Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

2026-02-11 - 12:38

SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ — Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) (“Ribo”) and its subsidiary Ribocure Pharmaceuticals AB (“Ribocure”) today announced that they have entered into an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) for six pre-clinical small interfering RNA (siRNA) programs for the